Comprehensive Guide to Hepatitis Advances

Wai-Kay Seto, MBBS, MD, FRCP, is a Clinical Professor in the Department of Medicine and Principal Investigator of the State Key Laboratory of Liver Research, the University of Hong Kong, Hong Kong. Prof. Seto is currently ranked by Clarivate Analytics in?the top 1% worldwide by research. He has published more than 230 international journal articles and book chapters, including leading-authored articles in The?Lancet,? Journal of Clinical Oncology, Lancet Global Health, Journal of Hepatology, Gut, Hepatology, ?and? Clinical Infectious Diseases, majority related to research on chronic liver diseases. He was part of a Chinese Medical Association expert panel that wrote the first chronic hepatitis B guideline for primary care physicians in Mainland China. Mohammed Eslam, MBBS, MSc, PhD, is a Professor of hepatology in the Storr Liver Centre, Sydney University, and the Head of the genetics and fatty liver group at Storr Liver Centre at the Westmead Institute for Medical Research. He heads the international liver disease genetic consortium. Prof. Eslam is currently ranked by Scival and Expertscape in the top 0.1% worldwide in fatty liver disease research. He has published more than 135 international journal articles and 5 book chapters, including leading-authored articles in the The Lancet, Nature Genetics, Nature Communications, Nature Reviews of Gastroenterology and Hepatology, The Lancet Gastroenterology and Hepatology, Gastroenterology, Gut, Hepatology, and Journal of Hepatology.

?Section 1:?HEPATITIS: ADVANCES IN CLINICAL EVALUATION 1. Noninvasive assessment of liver disease severity: image-related 2. Noninvasive assessments of liver disease severity based on biomarkers 3. Conventional liver imaging in hepatitis 4. Nutrition in liver disease

Section II: VIRAL HEPATITIS 5. Antivirals against hepatitis viruses: basic mechanisms 6. Hepatitis A and hepatitis E 7. Hepatitis B: epidemiology, natural history, and diagnosis 8. Hepatitis B: treatment 9. Hepatitis C: epidemiology, natural history, and diagnosis 10. Hepatitis C: treatment 11. Hepatitis D

Section III: HEPATITIS: METABOLIC, ALCOHOL, AND DRUG INDUCED 12. Metabolic-associated fatty liver disease: epidemiology, natural history and diagnosis, current paradigm and definitions for MAFLD 13. Metabolic-associated fatty liver disease: pharmacological management 14. Non-pharmacological treatment approach in patients with metabolic dysfunctionassociated liver disease 15. Alcoholic hepatitis 16. Drug-induced liver injury caused by conventional drugs, using cases based on the Roussel Uclaf causality assessment method 17. Introduction to drug-induced liver injury

Section IV: HEPATITIS: CHOLESTATIC, GENETIC, AND AUTOIMMUNE CAUSES 18. Current paradigm and treatment options for autoimmune hepatitis 19. Hereditary hemochromatosis 20. Wilson disease 21. Alpha-1 antitrypsin deficiency

Section V: HEPATITIS: INFECTIONS AND SYSTEMIC CAUSES 22. Hepatitis: infections and systemic causes 23. HIV: hepatic manifestations of HIV and antiretroviral therapy 24. Systemic non-infectious hepatitis 25. Concurrent HCV or fatty liver in patients with chronic hepatitis B virus infection

Section VI: CHILDHOOD AND PREGNANCY 26. Hepatitis during childhood 27. Hepatitis during pregnancy